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Abstract
Herpes simplex virus (HSV) types 1 and 2 (HSV-1 and HSV-2) are the most common infectious agents of humans.
No safe and effective HSV vaccines have been licensed. Reverse vaccinology is an emerging and revolutionary
vaccine development strategy that starts with the prediction of vaccine targets by informatics analysis of genome
sequences. Vaxign (http://www.violinet.org/vaxign) is the first web-based vaccine design program based on reverse
vaccinology. In this study, we used Vaxign to analyze 52 herpesvirus genomes, including 3 HSV-1 genomes, one
HSV-2 genome, 8 other human herpesvirus genomes, and 40 non-human herpesvirus genomes. The HSV-1 strain
17 genome that contains 77 proteins was used as the seed genome. These 77 proteins are conserved in two other
HSV-1 strains (strain F and strain H129). Two envelope glycoproteins gJ and gG do not have orthologs in HSV-2 or
8 other human herpesviruses. Seven HSV-1 proteins (including gJ and gG) do not have orthologs in all 40 non-
human herpesviruses. Nineteen proteins are conserved in all human herpesviruses, including capsid scaffold protein
UL26.5 (NP_044628.1). As the only HSV-1 protein predicted to be an adhesin, UL26.5 is a promising vaccine target.
The MHC Class I and II epitopes were predicted by the Vaxign Vaxitop prediction program and IEDB prediction
programs recently installed and incorporated in Vaxign. Our comparative analysis found that the two programs
identified largely the same top epitopes but also some positive results predicted from one program might not be
positive from another program. Overall, our Vaxign computational prediction provides many promising candidates
for rational HSV vaccine development. The method is generic and can also be used to predict other viral vaccine
targets.
Background
The Herpesviridae are a family of DNA viruses that
cause diseases in humans and various animals. Herpes-
viruses are the members of the Herpesviridae family. All
herpesviruses share a similar virion structure: a linear,
double-stranded DNA molecule densely packaged into
an icosahedral protein cage called capsid. The capsid is
surrounded by an amorphous protein layer, called the
tegument, consisting of both viral proteins and viral
mRNAs and a lipid bilayer membrane (the envelope).
Infectious virions are spherical. All herpesviruses are
species-specific. Human herpesviruses (HHVs) include
eight members: Herpes simplex virus (HSV) type 1 and
2 (HSV-1 and HSV-2), varicella zoster virus (VZV;
HHV-3), Epstein-Barr virus (EBV; HHV-4), human cyto-
megalovirus (CMV; HHV-5), human herpesvirus-6 and
-7 (HHV-6 and HHV-7), and Kaposi’s sarcoma associated
herpesvirus (KSHV; HHV-8). Herpesviruses typically
cause latent, lytic, and recurring infections. HSV-1 and
HSV-2 are two human pathogens that cause a variety of
recurrent immunopathologic diseases, ranging from mild
skin diseases including herpes labialis and herpes genita-
lis to life-threatening diseases including neonatal herpes
and adult herpes encephalitis [1,2]. For example, HSV-1
can cause epithelial lesions on the lip or face. After estab-
lishment of productive infection, HSV-1 causes latent
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infection of the trigeminal ganglia. Despite fairly wide-
spread use of antiviral drugs, HSV-1 and HSV-2 remain
among the most common infectious agents of humans.
In the US, the seroprevalence of HSV-1 and HSV-2 in
adults is 68% and 21%, respectively; and approximately
700-2000 cases of neonatal HSV infections per year
occur in the US [3].
Although many acute infections can be controlled by
vaccination, the development of prophylactic and thera-
peutic vaccines against persistent herpesviruses remains
challenging. There are currently no US FDA-approved
HSV vaccines available. The development of an effective
vaccine against HSV is complicated by many unique
characteristics of herpes viruses, including the complexity
of the virus replication cycle (i.e., primary, latent and
recurrent phases of infection), their sophisticated immu-
noevasion strategies, a high number of protein candidates
by the large and complex herpes genome [2]. Although
antibodies generated following HSV-1 and HSV-2 immu-
nizations do not protect against virus entry, antibodies
against envelope glycoproteins gB, gC, gD, and gE pro-
vide passive protection against lethal viral challenges.
T helper cell type 1 (Th1) response and cytotoxic T lym-
phocyte (CTL) activities are also critical to the host pro-
tection [4]. Many HSV proteins, including two major
protective antigens gB and gD, have been evaluated for
vaccine development [5,6]. Although animal studies
showed induced protection, human clinical trials with
vaccines using these two proteins (gB and gD) have not
generated ideal results [5,6]. Therefore, for developing
safe and effective human HSV vaccines, it is necessary to
identify and evaluate more protective antigens in HSVs.
As an emerging and revolutionary vaccine development
approach, reverse vaccinology starts with the prediction of
vaccine protein targets by bioinformatics analysis of gen-
ome sequences [7]. Reverse vaccinology was first applied
to development of a vaccine against serogroup B Neisseria
meningitidis (MenB) [8]. With this method, it took less
than 18 months to identify more protective vaccine targets
in MenB than had been discovered during the past
40 years by conventional methods [8]. Afterwards, this
technology has been successfully applied to many other
pathogens such as Bacillus anthracis [9], Streptococcus
pneumoniae [10], Mycobacterium tuberculosis [11], and
Cryptosporidium hominis [12]. Vaxign is the first web-
based vaccine design software that uses the reverse vacci-
nology strategy [13,14]. In reverse vaccinology, predicted
proteins are selected based on defined desirable attributes.
Predicted features in the Vaxign pipeline include pro-
tein subcellular location, transmembrane helices, adhesin
probability, conservation among pathogenic strains,
sequence exclusion from genomes of nonpathogenic
strains, sequence similarity to host proteins, and epitope
binding to Major histocompatibility complex (MHC) class
I and class II. Vaxign has been demonstrated in successful
prediction of verified and potential vaccine targets for
Brucella spp. [14,15] and uropathogenic E. coli [13]. Over
200 genomes have been pre-computed using the Vaxign
algorithm and available for query in the Vaxign website.
Vaxign also allows for dynamic vaccine target prediction
based on users’ input sequences. Since the previous publi-
cation [13], Vaxign has included several new features.
For example, after log in, a user can save Vaxign analysis
projects for continuous updates and result sharing. While
Vaxign includes its own MHC class I and II epitope pre-
diction tool, Vaxign has now incorporated the tools imple-
mented in the Immune Epitope Database (IEDB; http://
tools.immuneepitope.org/main/html/tcell_tools.html).
Both sets of epitope prediction results can then be com-
pared in parallel.
The Vaxign reverse vaccinology approach is generic
and can be used for analyses of vaccines against various
pathogens and infection diseases. However, there has
not been a report of how to use Vaxign to predict vac-
cine targets for a viral disease. In this study, we have
used Vaxign to predict HSV vaccine targets.
Results
HSV genome data processing and Vaxign analysis
In total 52 herpesvirus genomes were identified from
NCBI RefSeq and GenBank databases (Table 1). These
genomes correspond to 52 herpesvirus strains from
humans and different animal species. Twelve genomes
come from human herpesviruses, covering all eight
human herpesvirus types. This study aimed to predict
herpes simplex virus vaccine targets, with an emphasis
on HSV-1. HSV-1 has three strains including strain 17
(RefSeq ID: NC_001806.1), strain F (GenBank accession
ID: GU734771.1), and strain H129 (GenBank accession
ID: GU734772.1) (Table 1).
Vaxign is a vaccine design pipeline that assembles a list
of separate software programs to calculate different criteria
for individual proteins. For the prediction of viral vaccine
targets, Vaxign allows a user to choose the following
criteria:
(i) Sequence conservation among different genomes, e.g.,
among HSV-1 genomes or among all human herpes-
viruses.
(ii) Sequence exclusion from specific genomes, e.g.,
those HSV-1 proteins that do not have orthologous pro-
teins in non-human herpesviruses.
(iii) Adhesin probability. Adhesin is critical for a virus
to invade a host cell. So adhesins turn to be good vac-
cine targets.
(iv) The number of transmembrane helices. The pre-
sence of more than one transmembrane helix of a protein
is often the result of failure of recombinant protein isola-
tion and purification [13]. Therefore, a user can choose
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Table 1 Fifty-two herpesvirus genomes used in current Vaxign analysis.
# Infected host Herpesvirus strains Genome # No of proteins
1 Hartebeest Alcelaphine herpesvirus 1 NC_002531.1 71
2 Anatids Anatid herpesvirus 1 NC_013036.1 77
3 Anguillida Anguillid herpesvirus 1 NC_013668.3 143
4 Atelinae Ateline herpesvirus 3 NC_001987.1 73
5 Bovinae Bovine herpesvirus 1 NC_001847.1 70
6 Bovinae Bovine herpesvirus 4 NC_002665.1 79
7 Bovinae Bovine herpesvirus 5 NC_005261.2 70
8 Callitrichidae Callitrichine herpesvirus 3 NC_004367.1 72
9 Cavy Caviid herpesvirus 2 NC_011587.1 106
10 Cercopithecinae Cercopithecine herpesvirus 2 NC_006560.1 75
11 Cercopithecinae Cercopithecine herpesvirus 9 NC_002686.2 74
12 Cyprinidae Cyprinid herpesvirus 3 NC_009127.1 160
13 Horse Equid herpesvirus 2 NC_001650.1 79
14 Horse Equid herpesvirus 4 NC_001844.1 79
15 Horse Equid herpesvirus 9 NC_011644.1 80
16 Cat Felid herpesvirus 1 NC_013590.2 77
17 Chicken Gallid herpesvirus 1 NC_006623.1 79
18 Chicken Gallid herpesvirus 2 NC_002229.3 85
19 Chicken Gallid herpesvirus 3 NC_002577.1 76
20 Human Human herpesvirus 1 strain 17 NC_001806.1 77
21 Human Human herpesvirus 1 strain F GU734771.1 77
22 Human Human herpesvirus 1 strain H129 GU734772.1 77
23 Human Human herpesvirus 2 strain HG52 NC_001798.1 77
24 Human Human herpesvirus 3 NC_001348.1 73
25 Human Human herpesvirus 4 NC_009334.1 80
26 Human Human herpesvirus 4 type 1 NC_007605.1 94
27 Human Human herpesvirus 5 NC_006273.2 165
28 Human Human herpesvirus 6A NC_001664.2 88
29 Human Human herpesvirus 6B NC_000898.1 104
30 Human Human herpesvirus 7 NC_001716.2 86
31 Human Human herpesvirus 8 NC_009333.1 86
32 Catfish Ictalurid herpesvirus 1 NC_001493.1 90
33 Macaque monkey Macacine herpesvirus 1 NC_004812.1 75
34 Macaque monkey Macacine herpesvirus 3 NC_006150.1 223
35 Macaque monkey Macacine herpesvirus 4 NC_006146.1 80
36 Macaque monkey Macacine herpesvirus 5, genome NC_003401.1 89
37 Turkey Meleagrid herpesvirus 1 NC_002641.1 79
38 Mouse Murid herpesvirus 1 NC_004065.1 161
39 Mouse Murid herpesvirus 2 NC_002512.2 167
40 Mouse Murid herpesvirus 4 NC_001826.2 74
41 Oyster Ostreid herpesvirus 1 AY509253.1 127
42 Sheep Ovine herpesvirus 2 NC_007646.1 73
43 Panine Panine herpesvirus 2 NC_003521.1 165
44 Mouse Papiine herpesvirus 2 NC_007653.1 75
45 Psittacine birds Psittacid herpesvirus 1 NC_005264.1 77
46 Ranidae Ranid herpesvirus 1 NC_008211.1 132
47 Ranidae Ranid herpesvirus 2 NC_008210.1 147
48 Rodent Rodent herpesvirus Peru NC_015049.1 82
49 Squirrel monkey Saimiriine herpesvirus 1 NC_014567.1 70
50 Squirrel monkey Saimiriine herpesvirus 2 NC_001350.1 76
51 Suidae Suid herpesvirus 1 NC_006151.1 175
52 Tupaiid Tupaiid herpesvirus 1 NC_002794.1 158
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to not include those proteins with many transmembrane
helices as possible vaccine targets.
(v) MHC Class I and II epitopes. A protein with many
T cell epitopes is a preferred vaccine target. Also, pre-
diction of MHC Class I and II epitopes is critical for
those who plan to develop epitope vaccines.
Since different module software programs used in Vax-
ign are independent from each other, a user can choose
whether or not to use any specific criteria and programs.
Such module-based software pipeline is designed based on
the observation that vaccine researchers and developers
often have different preferences in terms which criteria to
use and how to use them for their specific vaccine design
applications. Below we present our predictions based on
the schemes considered appropriate for development of
HSV vaccines.
Vaxign prediction of HSV protein vaccine targets
The 52 herpesviruses into two groups: human herpes-
viruses and other animal herpesviruses. The human her-
pesviruses include three HSV-1 genomes, one HSV-2
genome, and eight human herpesvirus type 2-8 genomes.
We have chosen to use HSV-1 (or HHV-1) strain 17 as
the seed genome in our Vaxign analysis. The NCBI RefSeq
genome annotation record shows that this genome
includes 77 genes instead of the originally reported 72
genes [16]. The selection of this genome as a seed genome
means that every chosen comparison among genomes is
between the HSV-1 genome and other genome(s) and
Vaxign reports the results using the HSV-1 proteins. HSV
strain F and strain H129 were used for sequence conserva-
tion analysis. Our Vaxign analysis found that all 77 pro-
teins in strain 17 also exist in HSV-1 strains F and H129
(Figure 1).
After the conservation analysis among all three HSV1
genomes, we have performed different Vaxign analyses
using different schemes. First, our analysis identified two
HSV-1 proteins that are conserved in all HSV-1 genomes
but absent in all 9 genomes from seven other human her-
pesvirus types. These two proteins are envelope glycopro-
tein gJ (NP_044667.1) and envelope glycoprotein gG
(NP_044666.1). The HSV-2 genome (NC_001798.1) is
very similar to HSV-1 [17]. However, these two proteins gJ
and gG do not have orthologs in HSV-2. Therefore, gJ and
gG are likely critical to differentiate HSV-1 from HSV-2
and other human herpesviruses.
Seven out of 77 HSV-1 proteins were found absent in 40
non-human herpesviruses (Table 2). These seven proteins
may differentiate HSV-1 from all other non-human her-
pesviruses. Since herpesviruses are very species-specific,
the differentiation of orthologous proteins among human
and non-human herpesviruses provides a way to identify
the mechanism of host specificity of the viruses. These
proteins may also be valuable to generate human-specific
HSV-1 vaccines. However, an animal experiment with vac-
cine candidates using these proteins may not work out due
to the host specificity issue. Among the seven proteins are
two envelope glycoproteins gJ and gG, neurovirulent pro-
teins NP_044661.1 and NP_044600.1 (Note: they are para-
logs), transporter associated with antigen presentation
(TAP) inhibitor ICP47, tegument protein US11, and mem-
brane protein UL56. The two envelope glycoproteins were
predicted to have two transmembrane helices each. UL56
was predicted to have one trans-membrane helix, which is
consistent with the nature of UL56 being a membrane
protein. None of these proteins have a favorable adhesin
probability, indicating that they are not likely adhesins.
Among 77 HSV-1 proteins, 19 are conserved also
among nine other human herpesvirus (HHV) genomes
(Table 3). Among the 19 HSV-1 proteins, four are capsid
proteins, two are envelope glycoproteins, and five are
DNA packaging proteins. The two envelope glycoproteins
have three and eight transmembrane helices. The capsid
scaffold protein UL26.5 (NP_044628.1; http://www.ncbi.
nlm.nih.gov/protein/NP_044628.1) is the only one of the
19 proteins that has an adhesin probability of >0.51. This
suggests that UL26.5 is an adhesin HSV-1 protein.
Vaxign prediction of MHC Class I and II epitopes
Vaxitop is a Vaxign program that predicts MHC Class I
and II binding epitopes based on position specific scoring
matrices (PSSM) [13]. Currently many software programs
for predicting T cell MHC Class I and II epitopes are
available [18]. One unique feature about Vaxitop is that it
reports a statistics P-value while other MHC Class I and
II prediction tools typically report a percentage or top
number. It has been recognized that an incorporation of
different programs would increase the specificity of T cell
epitope prediction. Therefore, we have installed the
default IEDB MHC Class I and II prediction tools (http://
tools.immuneepitope.org/main/html/tcell_tools.html) in
Vaxign. A Vaxign user is allowed to calculate and com-
pare the immune epitopes by using both Vaxitop and
IEDB programs.
The addition of epitope prediction allows further analy-
sis for the existence of potential HSV vaccine targets. Our
analysis found that the HSV-1 UL26.5 capsid scaffold pro-
tein (NP_044628.1) [19] is particularly interesting. The
adhesin probability of this protein is 0.675, which is the
only protein that has an adhesin probability of more than
0.51, the default cutoff value of defining a predicted adhe-
sin. We have thus focused here on the immune epitope
predictions based on this capsid scaffold protein.
Our analyses found that the predicted results from the
Vaxitop and IEDB MHC Class I prediction program usually
overlap. Figure 2 provided an example when 10 amino acid
epitopes were predicted for human HLA*A0201 allele. In
this case, Vaxitop predicted three epitopes with a P-value
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cutoff value of 0.05 (Figure 2B and 2C) and six epitopes
with a P-value cutoff of 0.1. IEDB predicted 12 epitopes
with an IC50 cutoff of 10 and 109 epitopes for the same
allele. Both programs predicted the same top three hits
GLSQHYPPHV, HQYPGVLFSG, and DLFVSQMMGA.
The Vaxitop P-value score for top 1 epitope GLSQH-
YPPHV is 0.0212. The IEDB IC50 value is 1.05. Among the
six epitopes, five but one epitope was predicted by the IEDB
program to have an IC50 value of < 50. The results show
that these two programs predict similar top results but the
top results may differ slightly. In general, Vaxign-Vaxitop is
more conserved in producing the number of predicted
epitopes than the IEDB program within the current cutoffs
of these two programs. It is noted that we cannot provide
evidence that the other top-score hits predicted by IEDB
but not by Vaxitop are not significant.
Similarly, overlaping results could be found in MHC
Class II epitope prediction between the results predicted
from Vaxitop and the IEDB method (data not shown).
The results of our receiver operating characteristic (ROC)
curve data analyses using the positive and negative training
data obtained from the IEDB database were comparable to
the top results from existing MHC Class II prediction
tools that were surveyed by Wang et al [28]. The results of
Figure 1 The workflow and results of Vaxign prediction of HSV1 vaccine targets. The highlighted human herpesvirus 1 strain 17 was used
as the seed genome in the reported analysis.
Table 2 Seven HSV-1 proteins that do not have orthologs in all 40 non-human herpesviruses.
# Protein Accession Protein Note Adhesin Probability Trans-membrane helices
1 NP_044675.1 TAP transporter inhibitor ICP47 0.079 0
2 NP_044674.1 tegument protein US11 0.245 0
3 NP_044667.1 envelope glycoprotein gJ 0.176 2
4 NP_044666.1 envelope glycoprotein gG 0.419 2
5 NP_044659.1 membrane protein UL56 0.238 1
6 NP_044661.1 neurovirulence protein ICP34.5 0.228 0
7 NP_044600.1 neurovirulence protein ICP34.5 0.228 0
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the ROC analyses are provided in the Vaxign web page
(http://www.violinet.org/vaxign/docs/aucs.php).
Discussion
One major bottleneck for developing an effective and safe
human HSV vaccine(s) is to identify protective antigens
that are conserved among all HSV genomes and are able
to induce protective immune response. Our current study
is the first time to use a reverse vaccinology strategy to
analyze various herpesvirus genomes and identify possible
HSV vaccine targets based on genome sequence analyses.
Our Vaxign reverse vaccinology approach has proven to
be an efficient method to predict many valuable vaccine
targets that are conserved in HSV genomes and contain
desired characteristics.
Current study provides many vaccine targets for HSV
vaccine development, including seven HSV-1 proteins that
do not have orthologs in all tested non-human herpes-
viruses (Table 2). Among them are envelope glycoprotein gJ
and gG. Antibody against gG has been found in HSV-1
infected individuals’ serum samples [20]. HSV-1 gJ plays an
important role in neuron-to-neuron transmission through
synaptically linked neuronal pathways [21]. The membrane
protein UL56 is likely involved in vesicular trafficking in
HSV-infected cells [22]. HSV-1 ICP34.5 protein is a neuro-
virulence factor that plays critical roles in viral replication
and anti-host responses [23]. HSV-1 ICP47, one of the
seven proteins, is an early expressed protein that blocks the
MHC class I antigen presentation pathway by binding to
the TAP transporter [24]. These HSV proteins that do not
have orthologs in non-human herpesviruses may be valu-
able human vaccine targets.
We have also found 19 HSV-1 proteins that are also con-
served in other human herpesviruses (Table 3). This list
includes two envelope glycoproteins gM and gB, five DNA
packaging related proteins, and four capsid related proteins.
Our analysis has identified capsid scaffold protein UL26.5 as
a promising vaccine target. The primary reason is that
UL26.5 is the only protein among all 77 HSV-1 proteins
that has an adhesin probability of >0.51. The UL26.5 capsid
scaffold protein is known to be critical for virus capsid for-
mation [19]. During the assembly of a HSV capsid, the
major capsid protein VP5 interacts with the C-terminal resi-
dues of the scaffold proteins UL26.5 and UL26 (also one of
the 19 proteins in Table 3). After capsid assembly the scaf-
fold proteins are cleaved at the maturation site by a serine
protease also encoded by UL26, thereby allowing the scaf-
fold proteins to be released from the capsid [25,26]. The
cleaved UL26.5 protein releases the major scaffold protein
VP22a. It is likely that the other cleaved segment plays a cri-
tical role in making UL26.5 a possible adhesin. An HSV-1
mutation with a deletion of UL26.5 amino acids 143-150 is
unable to produce infectious virus [27]. It suggests that
UL26.5 is a virulence factor critical for viral pathogenesis.
UL26.5 is one of the 19 HSV-1 proteins that are also con-
served in other human herpesviruses (Table 3). It means
that this protein can be potentially used to develop a vac-
cine against all human herpesviruses. Experimental study is
required to verify the value of UL26.5 or part of UL26.5 as a
protective antigen for HSV vaccine development.
Table 3 19 HSV-1 proteins that are also conserved in other human herpesviruses.
# Protein Accession Protein GI Protein Note Adhesin Probability Trans-membrane helices
1 NP_044603.1 9629382 uracil-DNA glycosylase 0.262 0
2 NP_044606.1 9629385 helicase-primase helicase subunit 0.115 0
3 NP_044655.1 9629434 helicase-primase primase subunit 0.163 0
4 NP_044607.1 9629386 capsid portal protein 0.241 0
5 NP_044620.1 9629399 major capsid protein 0.113 0
6 NP_044627.1 9629406 capsid maturation protease (UL26) 0.386 0
7 NP_044628.1 9629407 capsid scaffold protein UL26.5 0.675 0
8 NP_044611.1 9629390 envelope glycoprotein gM 0.244 8
9 NP_044629.1 9629408 envelope glycoprotein gB 0.229 3
10 NP_044613.1 9629392 deoxyribonuclease 0.203 0
11 NP_044616.1 9629397 DNA packaging terminase subunit 1 0.165 0
12 NP_044630.1 9629409 DNA packaging terminase subunit 2 0.188 0
13 NP_044626.1 9629405 DNA packaging tegument protein UL25 0.210 0
14 NP_044634.1 9629413 DNA packaging protein UL32 0.185 0
15 NP_044635.1 9629414 DNA packaging protein UL33 0.264 0
16 NP_044625.1 9629404 nuclear protein UL24 0.195 0
17 NP_044631.1 9629410 single-stranded DNA-binding protein 0.168 0
18 NP_044632.1 9629411 DNA polymerase catalytic subunit 0.101 0
19 NP_044641.1 9629420 ribonucleotide reductase subunit 1 0.193 0
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Figure 2 Vaxign prediction of MHC Class I HLA-A*0201 immune epitopes of HSV-1 UL26.5 capsid scaffold protein using Vaxign-
Vaxitop program and IEDE prediction program. (A) Selection of parameters for epitope prediction. (B) Display of the locations of all
predicted epitopes in the whole length protein. (3) Comparison of predicted results between Vaxitop and IEDB program. The label “consistent”
means that the circled results were predicted by both programs. The label “inconsistent” indicates that the circled result was predicted to be
positive by Vaxitop but not by IEDB program.
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Various T cell MHC Class I and II epitope prediction
algorithms have been developed and use different predic-
tion approaches [18]. In general, T cell epitope algorithms
have now achieved a high degree of prediction accuracy
[28]. Different from other T cell epitope methods, Vaxitop
uses a statistical P-value [13], which is more understand-
able to many biologists. Our comparative analysis found
that Vaxitop predicted MHC Class I epitope results overlap
with the IEDB prediction method and Vaxitop usually pre-
dicts less positive hits than the IEDB prediction (Figure 2).
Since it is often that many epitopes are identified, it may be
safe to experimentally test those epitopes that are positive
from both predictions. The incorporation of these IEDB
MHC Class I and II methods also provides the Vaxign
users more options to perform immune epitope analysis.
The Vaxign vaccine design program can also be
improved with additional features. For example, Vaxign
lacks a program to predict the location of a viral protein
inside the virion particle and its subcellular location inside
host cells. Currently Vaxign includes PSORTb, a program
that is designed for bacterial subcellular location predic-
tion [29]. Another program for viral protein location
would be needed, especially for those viruses containing a
large genome. Since different criteria are provided in Vax-
ign, it is often a user’s choice to balance the criteria for
vaccine candidate selection. To make the selection more
balanced, we are currently designing a comprehensive
score that ranks predicted proteins by integrating different
criteria. We are also in the process of incorporating gene
expression profiles of microbial genes at different experi-
mental conditions into our rational vaccine design. As an
integrated component of the web-based VIOLIN database
and analysis system (http://www.violinet.org) [30], Vaxign
can also be improved by interaction with other VIOLIN
programs. For example, VIOLIN Protegen is a web-based
database that contains over 600 protective antigen infor-
mation [31]. These experimentally verified protective anti-
gens can be used for identifying specific patterns in
protective antigens and computationally predicting protec-
tive antigens [32]. Many of the protective antigens in
Protegen come from viruses, thus they can be used for the
training of the Vaxign program and the verification of pre-
dicted results. The vaccine adjuvant database Vaxjo [33] in
VIOLIN may provide training data for Vaxign to include a
specific component for rational vaccine adjuvant design.
The community-based Vaccine Ontology (VO; http://
www.violinet.org/vaccineontology) is developed to support
vaccine data standardization, integration, and computer-
assisted reasoning [34]. VO has been found to be valuable
in ontology-based natural language processing and litera-
ture mining [35], which can facilitate advanced vaccine
design [36]. Currently, we are exploring how VO-based lit-
erature mining can improve Vaxign vaccine design.
Methods
Extraction and processing of herpesvirus genomes from
NCBI
In total 52 herpesvirus genomes were retrieved from
NCBI RefSeq [37] and GenBank [38] databases. The
protein sequences were extracted and stored in the Vax-
ign relational database.
Vaxign prediction of herpesvirus proteins as vaccine
targets
For each herpesvirus protein, the Vaxign pipeline was
used to calculate various criteria using module software
programs described below:
• Subcellular localization. This feature is implemen-
ted in Vaxign using optimized PSORTb 3.0 [29].
PSORTb is the most precise bacterial protein subcellular
localization predictor. To use this program, Vaxign first
develops a script to generate standard input data for
PSORTb. After the PSORTb execution, Vaxign automa-
tically parses the PSORTb output and stores the results
into the Vaxign MySQL database. Such a process allows
seamless generation of PSORTb input, execution, and
automatic processing and storage of PSORTb output in
Vaxign. Similar strategies have been used in using other
module programs.
• Number of transmembrane helices. The trans-
membrane helix topology analysis is conducted using
optimized HMMTOP [14].
• Minimum adhesin probability (0-1.0). Optimized
SPAAN program [16] is used for calculating adhesin
probability. A probability of greater than the default cut-
off of 0.51 indicates that a tested protein is likely an
adhesin or obtains adhesin-like characteristics. With this
cutoff, the performance of the SPAAN program is opti-
mized with the highest Matthews correlation coefficient
[39].
• Microbial sequence conservation by ortholog ana-
lysis. OrthoMCL is applied for finding conserved pro-
teins among a selected list of strains [17]. The E-value
of 105 is set as the default value for OrthoMCL
processing.
• Exclusion of proteins having orthologs in selected
genome(s). Similarly, OrthoMCL is applied for exclud-
ing proteins that also exist in a non-pathogenic strain(s).
• No similarity to host proteins. Choose this selec-
tion to exclude those vaccine targets that also exist in a
host, including human, mouse, or pig.
Vaxign-Vaxitop prediction of MHC Class I and II epitopes
Vaxign includes an internally developed program called
Vaxitop, for prediction of MHC Class I & II epitopes.
Vaxitop predicts immune epitopes based on position
specific scoring matrices (PSSM). Different from other
Xiang and He BMC Bioinformatics 2013, 14(Suppl 4):S2
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existing epitope prediction algorithms, Vaxitop calcu-
lates statistical P-value (instead of a percentage or top
number) as the cutoff. A P-value of 0.05 provides a cut-
off with high and balanced sensitivity and specificity
[13]. We have also used Vaxitop to predict MHC Class
I & II epitopes for each herpesvirus protein.
Installation and incorporation of IEDB MHC Class I and II
epitope prediction programs in Vaxign
As a new Vaxign feature, the IEDB MHC Class I and II
epitope predictions programs have been downloaded
from the IEDB website (http://tools.immuneepitope.org/
main/html/tcell_tools.html). For each queried protein,
these IEDB tools can be used to dynamically predict
immune epitopes. The predicted results can be directly
compared with the results output by Vaxitop.
Query and analysis of herpesvirus vaccine targets using
Vaxign web interface
After all proteins from 52 herpesvirus genomes were
pre-computed, the results were made available for auto-
matic query and deep analysis using the Vaxign web
interface (http://www.violinet.org/vaxign).
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